Vincerx Pharma, Inc.
VINCDelisted Apr 28, 2025- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001796129
Vincerx Pharma, Inc. was delisted on Apr 28, 2025; its insiders filed their last Form 4 on Aug 14, 2024; 14 institutions reported holding it in 13F filings for Q1 2025, worth $116.8K in total; no superinvestor held it.
Key figures
- Insider buys
- 0
- Open market, last 90 days
- Insider sells
- 0
- Open market, last 90 days
- 13F holders
- 14
- Q1 2025, −7 vs. previous quarter
- 13F value
- $116.8K
- Reported value at the end of Q1 2025
- Superinvestors holding
- 0
- At the end of Q1 2025
Superinvestors holding VINC, Q1 2025
No superinvestor reported holding VINC at the end of Q1 2025.
Latest insider trades
Open-market purchases and sales by Vincerx Pharma, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Aug 14, 2023 (view filing) | Aug 11 | 3 days | Seelenberger Alexander A.See Remarks | PPurchase | +10.5K | $0.95 | +$9.97K | +53.1%30.3K after | |
| Aug 10, 2023 (view filing) | Aug 9-10 | 1 day | Hamdy Ahmed MDSee Remarks | PPurchase | +22.3K | $0.9524 | +$21.2K | +30.2%96.1K after | 2 lots |
| Aug 10, 2023 (view filing) | Aug 10 | Same day | Thomas Tom CSee Remarks | PPurchase | +5.00K | $0.95 | +$4.75K | +2.3%219.9K after | |
| Aug 10, 2023 (view filing) | Aug 9-10 | 1 day | Izumi Raquel E.See Remarks | PPurchase | +16.5K | $0.9063 | +$14.9K | +24.0%85.2K after | 2 lots |
| Dec 14, 2022 (view filing) | Dec 14 | Same day | Izumi Raquel E.See Remarks | PPurchase | +28.7K | $0.88 | +$25.3K | +71.8%68.7K after | |
| Dec 14, 2022 (view filing) | Dec 14 | Same day | Hamdy Ahmed MDChief Executive Officer | PPurchase | +35.3K | $0.87 | +$30.7K | +91.7%73.8K after | |
| Dec 14, 2022 (view filing) | Dec 14 | Same day | Thomas Tom CSee Remarks | PPurchase | +7.00K | $0.83 | +$5.81K | +233.3%10.0K after | |
| Aug 26, 2022 (view filing) | Aug 24-25 | 2 days | Lowe Christopher P.Director | PPurchase | +30.0K | $1.65 | +$49.5K | +300.0%40.0K after | 2 lots |
| Jun 29, 2022 (view filing) | Jun 27 | 2 days | Izumi Raquel E.See Remarks | PPurchase | +40.0K | $1.41 | +$56.4K | New position40.0K after | |
| Jun 27, 2022 (view filing) | Jun 23 | 4 days | Hamdy Ahmed MDChief Executive Officer | PPurchase | +24.2K | $1.41 | +$34.1K | +169.5%38.5K after |
Top 10 13F holders, Q1 2025
The largest institutional positions in Vincerx Pharma, Inc. at the end of Q1 2025; share changes are against Q4 2024.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Sage Rhino Capital LLC | 85,170 | $45.1K | 0.01% | 00.0% | UnchangedConverted for a 1-for-20 split |
| Citadel Advisors LLC | 42,777 | $22.6K | 0.00% | +42,777 | New |
| Goldman Sachs Group Inc | 31,567 | $16.7K | 0.00% | 00.0% | UnchangedConverted for a 1-for-20 split |
| Geode Capital Management, LLC | 19,285 | $10.2K | 0.00% | +7,209+59.7% | AddedConverted for a 1-for-20 split |
| Vanguard Group Inc | 14,317 | $7.57K | 0.00% | 00.0% | UnchangedConverted for a 1-for-20 split |
| Two Sigma Securities, LLC | 11,053 | $5.85K | 0.00% | +11,053 | New |
| Millennium Management LLC | 10,798 | $5.72K | 0.00% | +10,798 | New |
| Tower Research Capital LLC (TRC) | 2,997 | $1.59K | 0.00% | +2,997 | New |
| BlackRock, Inc. | 2,352 | $1.25K | 0.00% | 00.0% | UnchangedConverted for a 1-for-20 split |
| UBS Group AG | 142 | $75 | 0.00% | −4,497−96.9% | ReducedConverted for a 1-for-20 split |